Drug Trial Radar · NCT06161974
Study of Olutasidenib and Temozolomide in HGG
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Jun 2029
Study completion Jun 2035
Sponsor
- Lead sponsor
- Rigel PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Nationwide Children's Hospital
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Conditions
- High Grade Glioma
- Astrocytoma
- Astrocytoma, Grade III
- Astrocytoma, Grade IV
- Diffuse Intrinsic Pontine Glioma
- WHO Grade III Glioma
- WHO Grade IV Glioma
- Metastatic Brain Tumor
- Diffuse Midline Glioma, H3 K27M-Mutant
- Thalamus Tumor
- Spinal Tumor
- IDH1 Mutation
- IDH1 R132
- IDH1 R132C
- IDH1 R132H
- IDH1 R132S
- IDH1 R132G
- IDH1 R132L
- Oligodendroglioma
Interventions
Olutasidenib + TMZDrug
Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)Time frame: Completion of cycle 1 (28 days) for 6-24 patients
- Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)Time frame: From date of diagnosis until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up 24 months
- Maximum plasma concentration [Cmax] of OlutasidenibTime frame: From Day 1 of treatment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 24 months
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado · Not yet recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Not yet recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Susan Chi
Boston, Massachusetts · Not yet recruiting
Duke University Health System
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Not yet recruiting
Texas Children's Hospital
Houston, Texas · Not yet recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Sydney Children's Hospital
Randwick, New South Wales, Australia · Recruiting
Queensland Children's Hospital
South Brisbane, Queensland, Australia · Not yet recruiting
Perth Children's Hospital
Perth, Western Australia, Australia · Recruiting
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada · Not yet recruiting
Montreal Children's Hospital
Montreal, Quebec, Canada · Not yet recruiting
Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting
Princess Máxima Center
Utrecht, Netherlands · Not yet recruiting
Starship Children's Hospital
Auckland, Grafton, New Zealand · Not yet recruiting
Great Ormond Street Hospital
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.